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ABSTRACT
Aims/Introduction: To develop a non-invasive risk score to identify Saudis having pre-
diabetes or undiagnosed type 2 diabetes.
Methods: Adult Saudis without diabetes were recruited randomly using a stratified two-
stage cluster sampling method. Demographic, dietary, lifestyle variables, personal and fam-
ily medical history were collected using a questionnaire. Blood pressure and anthropomet-
ric measurements were taken. Body mass index was calculated. The 1-h oral glucose
tolerance test was carried out. Glycated hemoglobin, fasting and 1-h plasma glucose were
measured, and obtained values were used to define prediabetes and type 2 diabetes (dys-
glycemia). Logistic regression models were used for assessing the association between var-
ious factors and dysglycemia, and Hosmer–Lemeshow summary statistics were used to
assess the goodness-of-fit.
Results: A total of 791 men and 612 women were included, of whom 69 were found
to have diabetes, and 259 had prediabetes. The prevalence of dysglycemia was 23%,
increasing with age, reaching 71% in adults aged ≥65 years. In univariate analysis age,
body mass index, waist circumference, use of antihypertensive medication, history of
hyperglycemia, low physical activity, short sleep and family history of diabetes were statisti-
cally significant. The final model for the Saudi Diabetes Risk Score constituted sex, age,
waist circumference, history of hyperglycemia and family history of diabetes, with the
score ranging from 0 to 15. Its fit based on assessment using the receiver operating char-
acteristic curve was good, with an area under the curve of 0.76 (95% confidence interval
0.73–0.79). The proposed cut-point for dysglycemia is 5 or 6, with sensitivity and specificity
being approximately 0.7.
Conclusion: The Saudi Diabetes Risk Score is a simple tool that can effectively distin-
guish Saudis at high risk of dysglycemia.
INTRODUCTION
The rising prevalence of type 2 diabetes globally, and its subse-
quent socioeconomic burden imposes a challenge to govern-
ments of all countries1. Prediabetes precedes the development
of type 2 diabetes by several years2–4. In most cases, predia-
betes remains undiagnosed, and hence untreated, allowing fur-
ther deterioration in metabolic regulation, and worsening of
vascular complications2–4, leading to an increased risk of pro-
gressing to diabetes, and developing cardiovascular disease3,5.
Fortunately, type 2 diabetes is preventable, and might be evenReceived 4 July 2019; revised 3 January 2020; accepted 13 January 2020
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reversed, as proven by various studies6–12. Efforts to prevent
type 2 diabetes need to start as early as possible, and address
various susceptibility factors, many of which might be popula-
tion specific. Hence, identifying people at high risk for type 2
diabetes early will be an important component to prevent new
cases, and reduce costs8,9,12. Some available risk-assessment
models for diabetes require specific laboratory tests after diag-
nostic assessment13–15, hence they are not practical tools for
the assessment of risk in large population screening16. How-
ever, screening tools, such as non-laboratory risk scores, which
only require information a participant can self-complete, offer
an efficient method in identifying individuals with asymp-
tomatic type 2 diabetes and prediabetes. Parameters included
in such non-laboratory risk scores have been those that are
known risk factors for type 2 diabetes. The usually included
predictor variables have been: age, indicators of obesity, physi-
cal inactivity, indicators of diet, family history of type 2 dia-
betes, hypertension and history of disturbances of glucose
metabolism. Also, other factors, such as sleep disturbances,
smoking history, sitting time and so on might be considered as
non-laboratory parameters for a diabetes risk score.16–21
One of the first risk scores to be developed was the Finnish
Diabetes Risk Score (FINDRISC)16, which has been used in the
Finnish primary healthcare system to identify high-risk individ-
uals who might benefit from interventions, or who would merit
further investigation using the oral glucose tolerance test
(OGTT)10,17. Various risk score models based on the FIN-
DRISC were validated and developed further, and used in other
countries18–20. However, modifications were required to
improve specificity and sensitivity as a result of the genetics
and lifestyle characteristics of each population18–21.
Saudi Arabia has one of the highest diabetes prevalence glob-
ally22. Efforts to combat this epidemic have not been successful
so far, considering the noted rise over the years23–26. In view of
this, identifying individuals with asymptomatic type 2 diabetes
and prediabetes (i.e., dysglycemia) in the Saudi population is
becoming of utmost importance, especially as there is a long
asymptomatic period before type 2 diabetes can be detected3,7,
and as many newly diagnosed patients already show evidence
of microvascular complications7,27. Targeted screening for dysg-
lycemia with a screening questionnaire as a first step has been
shown to be successful in detecting dysglycemia and allowing
early intervention10,17–21. Attempts to construct a Saudi diabetes
risk score proposed previously28–30 included various limitations
preventing their wide adoption.
Therefore, we aimed to develop a valid and easy to adminis-
ter tool, so that the selection of variables and their relative
weights to be included in the Saudi Diabetes Risk Score
(SADRISC) are best suited to identify Saudi individuals who
have undiagnosed type 2 diabetes or prediabetes. Furthermore,
because of the variation in the differences in genetics and life-
style characteristics between the Finnish and the Saudi people,
and the expected effect on the used risk score, we aimed to
compare the performance of the developed model (i.e., sensi-
tivity and specificity) with the FINDRISC predictive model16.
METHODS
Study design
A cross-sectional design was used to recruit adult Saudis free of
known diabetes from public healthcare centers (PHCCs), using
a stratified two-stage cluster sampling method between July
2016 and February 201731. During the first stage, three PHCCs
from each of the five geographical sectors in Jeddah were
selected randomly. In the second stage, suitable individuals
(adults aged ≥20 years not previously diagnosed with diabetes)
were included using systematic sampling, until reaching target
sample size, which was calculated based on a previous study in
Jeddah26. Individuals with previously diagnosed diabetes, cancer,
renal or liver disease, cardiovascular disease, gastrointestinal dis-
eases requiring a special diet, physical or mental disabilities and
pregnant women were excluded.
A total sample size of 1500 (750 men and 750 women) was
targeted, with 300 individuals in each 10-year age stratum (20–
29, 30–39, 40–49, 50–59, ≥60 years). Sample size was calculated
for each center to reflect population density.
Ethical approval was obtained from the Committee on Ethics
of Human Research at Faculty of Medicine, King Abdulaziz
University, and Committee on Research Ethics at Ministry of
Health, Kingdom of Saudi Arabia.
Data collection
A questionnaire in Arabic was designed to collect information
covering demographic (age, sex, etc.), dietary (intake of fruit,
vegetable, red meat, bread and cereals, hot and cold beverages)
and lifestyle variables (physical activity, sleep duration, sitting
hours and smoking habits), as well as medical history, includ-
ing, present medication, previous dysglycemia, dyslipidemia and
family history of chronic diseases. Collected information was
chosen based on previous factors found to be associated with
dysglycemia in other populations5–12,16,19–21. Medical students
were trained to carry out interviews and perform other required
tasks.
After recruitment, participants signed a consent form, and
were instructed to fast overnight for 8–14 h. At the second
visit, a fasting blood sample was taken, for determination of
fasting plasma glucose (FPG) and glycated hemoglobin
(HbA1c), followed by ingestion of 50-g glucose solution
(CASCO NERL Diagnostics, East Providence, RI, USA), then
another sample was drawn 1 h later for estimation of glucose
(1-h OGTT)32,33. For glucose, sodium-citrate tubes were used,
and blood samples were immediately placed on ice and
transported to King Abdulaziz University, where plasma was
separated and frozen at -80°C. For HbA1c, ethylenediaminete-
traacetic acid tubes were used and stored at 4°C for later analy-
sis at the end of each working week. While waiting, data
collectors took anthropometric measurements, and blood
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pressure (BP) using standardized equipment and techniques.
Height was measured bare footed to the nearest 0.5 cm using a
stationary stadiometer. Weight was measured to the nearest
0.5kg while wearing light street clothing using a portable cali-
brated scale (Omron BF511; OMRON Healthcare, Kyoto,
Japan). These measurements were used to calculate body mass
index (BMI). Waist circumference (WC) was measured at the
midway between the lowest rib and iliac crest to the nearest
0.5 cm. Using WC to indicate abdominal adiposity, the first
cut-off value for increased risk was defined as >94 cm for men
and >80 cm for women, and the second cut-off value as
>102 cm for men and >88 cm for women34,35. BP was mea-
sured using an electronic sphygmomanometer (KBM Mercurial
Desk type SM-300; Kawamoto Corporation, Osaka, Japan).
Two BP readings were taken after the person has been seated
for 10 min within an interval of 1 min, and the average of the
two readings was calculated. If a difference >5 mmHg between
these two measures was found, a third measurement was
taken and the average of the two closest values was calculated.
Hypertension was defined as systolic BP ≥140 mmHg and/or
diastolic BP ≥90 mmHg, or current use of antihypertensive
medication36.
Biochemical assays
Whole blood and plasma samples were regularly sent to an
accredited clinical chemistry laboratory at the National Guard
Hospital in Jeddah. HbA1c was measured with high-pressure
liquid chromatography using automated HbA1c analyzer G8
(TOSOH Corporation, Yamaguchi, Japan). Plasma glucose was
measured by spectrophotometric methods using an Architect
c8000 auto-analyzer (Abbott, Abbott Park, IL, USA).
Definitions of diabetes and prediabetes
Prediabetes was defined as HbA1c 5.7–6.4% (39–46 mmol/
mol), FPG 6.1–6.9 mmol/L (impaired fasting glucose) or 1-h
plasma glucose (1-hPG) 8.6-11.0 mmol/L (impaired glucose
tolerance). Participants with HbA1c ≥6.5%, FPG ≥7 mmol/L or
1-h OGTT ≥11.1 mmol/L were considered to have dia-
betes33,37–39. People with either prediabetes or diabetes were
considered to have dysglycemia.
Statistical analysis
Data were analyzed using IBM SPSS statistics version 20.0 for
Windows (IBM Corporation, Armonk, NY, USA). Descriptive
statistics, frequencies, mean and standard deviation were used
to describe the baseline characteristics of the study population.
Multicollinearity diagnostics were carried out to check for cor-
relations between independent variables. BMI and WC showed
a correlation >0.6, and thus exceeded the threshold of indicat-
ing multicollinearity. In the final risk score model, only WC
was included. Unadjusted and adjusted logistic regression mod-
els were used for assessing the association between sociodemo-
graphic risk factors and lifestyle habits and outcome variables:
prediabetes, type 2 diabetes and dysglycemia. Hosmer–
Lemeshow summary statistics were used to assess the good-
ness-of-fit of the model. The level of statistical significance was
set to 0.05.
First, univariate logistic regression analysis was carried out to
determine which variables were significantly associated with
dysglycemia. Second, these variables were included in multivari-
ate models to develop the final model of the SADRISC. After
methodology for the development of the FINDRISC, logistic
regression was used to compute b-coefficients for known risk
factors for type 2 diabetes. Coefficients (b) of the model were
used to assign a score value for each variable, and the compos-
ite diabetes risk score was calculated as the sum of those scores.
The total dysglycemia risk score value was defined using the
full model, from the b-coefficient, as follows: for b = 0.01–0.49,
the score was 1; for b = 0.50–0.9, the score was 2; for b = 0.9–
1.2 the score was 3; for b = 1.2–1.6, the score was 4; and for b
>1.6, the score was 5. The lowest category (reference) of each
variable was given a score of 0. Total dysglycemia risk score
was calculated as the sum of the individual scores.
The receiver operating characteristic curve was developed,
and sensitivity, specificity, and positive and negative predictive
values were calculated for the SADRISC for several cut-off
points. The SADRISC was also tested against the FINDRISC
model.
RESULTS
A total of 1,477 adults were recruited; however, except for WC,
all other data were available for 1,403 people. WC measure-
ments were available for 1,376 participants. In most of the
excluded cases, laboratory samples were missing for various rea-
sons (hemolysis, missing labels or broken tubes). The mean age
was 32 – 11.5 years; 32 – 10.7 for men and 34 – 12.4 for
women, ranging from 20 to 81 years. The characteristics of the
studied population are presented in Table 1.
In laboratory assessments, 69 people were found to have dia-
betes (49 men and 20 women), and 259 had prediabetes (146
men, and 113 women). Figure 1 shows the proportion of peo-
ple identified with dysglycaemia through each of the three used
measures of glycemia. A total of 60% of participants were iden-
tified by 1-hPG (32% with 1-hPG alone), 59% by HbA1c (31%
with HbA1c alone), 19% using FPG (6% with FPG alone) and
just 28 participants (9%) of the entire sample with dysglycemia
had elevated values of all three measures of glycemia simultane-
ously.
Clinical and biochemical characteristics of participants by sex
are presented in Table 2. The prevalence of dysglycemia
increased with age (Table 3). Numerically, men showed a
higher prevalence than women, but it reached statistical signifi-
cance only in the age group 35–44 years. People with dysgly-
caemia were older, more obese and less physically active
(Table 4).
Table 5 shows the results from univariate analysis of the pre-
dictive ability of the eight variables included in the FINDRISC,
with sex and hours of sleep also included. Age, BMI, WC, use
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of antihypertensive medication, history of hyperglycemia, family
history of diabetes, low physical activity and short sleep were
all statistically significant, whereas diet (regular consumption of
fruit and vegetables) was not.
The final model for the SADRISC comprised five variables:
sex, age, WC, history of hyperglycemia and family history of
diabetes (Table 6). Because of multicollinearity with WC, BMI
was not included in the model. We carried out sensitivity
analysis using BMI instead of WC, and the results were almost
similar (data not shown). Score values range from 0 to 15. The
SADRISC model fit based on the assessment using the receiver
operating characteristic curve was reasonably good, with the
area under the curve of 0.76 (95% confidence interval 0.73–
0.79), being better than that for the FINDRISC (Figure 2).
Using different cut-points, the variation in sensitivity and
specificity is shown in Table 7. It seems that the most practical
Table 1 | Descriptive demographic, lifestyle and anthropometric characteristics of the Saudi Arabian Diabetes Risk Score study participants
Variable Total
(n = 1,403)
n (%)
Men
(n = 791)
n (%)
Women
(n = 612)
n (%)
Age group (years)
<35 926 (66) 566 (72) 360 (59)
35–44 261 (19) 134 (17) 127 (21)
45–54 135 (10) 53 (7) 82 (13)
55–64 60 (4) 25 (3) 35 (6)
>64 21 (1) 13 (2) 8 (1)
Body mass index (kg/m2)
<25 495 (35) 269 (34) 226 (37)
25–<30 493 (35) 293 (37) 200 (33)
≥30 415 (30) 229 (29) 186 (30)
Waist circumference (cm)
Normal (<94 cm men, <80 cm women) 523 (38) 332 (43) 191 (32)
Abdominal obesity level 1 (men >94–102, women >80–88) 330 (24) 213 (27) 117 (20)
Abdominal obesity level 2 (men >102, women >88) 523 (38) 237 (30) 286 (48)
Ethnic origin
Arabian tribes 1070 (76) 632 (80) 438 (72)
African tribes 72 (5) 29 (4) 43 (7)
Mediterranean countries 67 (5) 27 (3) 40 (7)
Indian continent 95 (7) 62 (8) 33 (5)
Central Asia 20 (1) 9 (1) 11 (2)
South East Asia 38 (3) 17 (2) 21 (3)
Mixed 41 (3) 15 (2) 26 (4)
Physical activity (30 min/day–5 days/week)
No 790 (56) 435 (55) 355 (58)
Yes 613 (44) 356 (45) 257 (42)
Sleep duration (h)
≤6 553 (40) 339 (43) 214 (35)
>6–8 720 (51) 408 (52) 312 (51)
>8 130 (9) 44 (5) 86 (14)
Sitting hours/day
<4 263 (18.7) 106 (13.4) 157 (25.7)
4–5 426 (30.6) 239 (30.2) 187 (30.6)
6–8 438 (31.2) 278 (35.1) 160 (26.1)
>8 276 (19.7) 168 (21.2) 108 (17.6)
Smoking habits
Non-smokers 956 (68.1) 447 (56.6) 509 (83.2)
Current smokers 303 (21.6) 261 (33) 42 (6.9)
Passive smokers 98 (7) 39 (4.9) 59 (9.6)
Previous smokers 46 (3.3) 44 (5.6) 2 (0.3)
Daily fruit or vegetable intake (at least one portion)
No 511 (36) 315 (40) 196 (32)
Yes 892 (64) 476 (60) 416 (68)
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cut-point to be used is 5 or 6, with sensitivity and specificity
being approximately 0.7, and they would label 43% and 39% of
the population to be at high risk, respectively. With 5 points,
everyone aged ≥55 years and with 6 points everyone aged
≥65 years were considered to be at high risk of dysglycaemia
(Table 3).
DISCUSSION
In order to help combat the rise in type 2 diabetes prevalence
in Saudi Arabia, we aimed to develop a non-invasive tool that
is best suited to identify Saudi individuals with a high risk of
undiagnosed type 2 diabetes or prediabetes. The present results
showed that the FINDRISC was operating reasonably well in
our population. However, the predictive validity of the devel-
oped SADRISC model was confirmed to be better with the area
under the curve of 0.76 compared with 0.71 for the FINDRISC.
Three previous attempts to develop type 2 diabetes risk
scores that included participants from Saudi Arabia have been
carried out28–30. However, each of them had serious limitations
preventing their use in practice. The first of these28 included
people from United Arab Emirates and Algeria in addition to
Saudis, and was part of a screening program for the detection
of diabetes in the three countries. Screening and recruitment of
participants was carried out in central locations in cities. Thus,
there was a strong selection bias, which would include a high
percentage of people suspecting that they might have type 2
diabetes. Furthermore, assessment was based on a self-
administered questionnaire, with a high percentage of partici-
pants having ≤9 years of schooling, introducing difficulties in
completing the questionnaire accurately. Furthermore, the diag-
nosis of diabetes and impaired glycemia was based on the mea-
surement of HbA1c alone, which is known to be insensitive for
detecting type 2 diabetes40, and not an appropriate method for
the studied population with a well-documented high prevalence
of hemoglobinopathies. Additional limitations were lack of stan-
dardization of equipment used for measurements, and variabil-
ity as a result of inadequate standardization of measurement
techniques.
HbA1c
31% (n = 103)
2% (n = 7) 17% (n = 57)
9% (n = 28)
FPG
6% (n = 20)
2% (n = 7) 1-hPG
32% (n = 106)
Figure 1 | Venn diagram for the detection of dysglycemia in the Saudi
glycemia screening participants. The cut-point for fasting plasma
glucose (FPG) was 6.1 mmol/L, 1-h post-challenge plasma glucose (1-
hPG) 8.6 mmol/L and glycated hemoglobin (HbA1c) 5.7%/
39 mmol/mol.
Table 2 | Clinical and biochemical characteristics in the Saudi Arabian Diabetes Risk Score participants
Variable Total
(n = 1,403)
Men
(n = 791)
Women
(n = 612)
FPG, mmol/L (mean – SD) 4.4 – 1.4 4.4 – 1.6 4.4 – 1.0
1-h, PG mmol/L (mean – SD) 6.6 – 2.6 6.6 – 2.9 6.6 – 2.2
HbA1c, % (mean – SD) 5.2 – 1.0 5.3 – 0.7 5.3 – 0.6
Mmol/mol (mean – SD) 34.6 – 7.0 34.7 – 7.4 34.5 – 6.5
SBP(mean – SD) 118 – 15 122 – 14 113 – 16
People with high values (n) 97 (6.9%) 62 (7.8%) 35 (5.7%)
DBP (mean – SD) 73 – 12 75 – 11 71 – 12
People with high values (n) 141 (10.0%) 88 (11.1%) 53 (8.7%)
People with hypertension (n) 222 (15.8%) 129 (16.3%) 93 (15.2%)
Use of blood pressure lowering medication (%) 4 3 6
Past history of hyperglycemia (in a medical checkup, during an illness or pregnancy) 8% 14%
Family history of diabetes mellitus (%)
Yes: grandparent, uncle, aunt or cousin 11 11 12
Yes: Biological father, mother or sibling 52 49 56
Score based on FINDRISC (mean – SD) 9 – 5 8 – 4 9 – 5
FINDRISC, Finnish Diabetes Risk Score.
ª 2020 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd J Diabetes Investig Vol.  No.   2020 5
O R I G I N A L A R T I C L E
http://wileyonlinelibrary.com/journal/jdi Dysglycemia risk score in Saudi Arabia
The second study29 included only a small sample of Saudis
from Riyadh (81 men and 20 women). In addition, only fasting
blood glucose was used to diagnose dysglycemia, which would
exclude those with impaired glucose tolerance requiring an
OGTT to be detected, and which constituted the majority of
people with dysglycemia among people free of known diabetes,
as also shown in the present study. Furthermore, no explana-
tion was given in the study of how anthropometric measure-
ments were carried out. The third and most recent30 included
participants from different regions of Saudi Arabia. The main
limitation was a lack of standardization of data collection, sur-
vey measurement techniques and laboratory measurements.
Indeed, no information was given on how glucose was mea-
sured, implying that it had been carried out at multiple labora-
tories, which is likely to introduce errors as a result of pre-
analytic and laboratory variability. In addition, almost half of
the participants were excluded from final statistical analyses for
various reasons. The AUC for screen-detected type 2 diabetes
and dysglycemia were only a modest 0.69 and 0.67, respectively.
Therefore, keeping in mind the limitations of these previous
studies, we aimed to carry out the present study in a standard-
ized manner.
By choosing the city of Jeddah, we hoped to ensure that
most socioeconomic sectors and ethnicities living in Saudi Ara-
bia were covered, due to its inhabitants forming a good repre-
sentative sample of the different ethnicities formulating the
actual Saudi population26. In addition, the present sample was
collected from PHCCs randomly selected from the five geo-
graphical sectors in Jeddah, to further ensure a good represen-
tation of the overall population having Saudi nationality. The
present results reflect the multiethnic nature of Saudis, with the
majority descending from Arabian tribes. Ethnic distribution in
the present study was not significantly different to that in our
previous survey carried out in the same city26, with persons
descending from Arabian tribes constituting 78% of the total
compared with 80% in present study.
Unlike several other similar diabetes risk score validation
studies, we applied the most comprehensive definition for dysg-
lycemia outcome, where a combination of HbA1c and OGTT
with both FPG and post-challenge glucose were all included.
Recently, several people have started to advocate the use of
1-hPG for the identification of prediabetes and dysglycemia32,40.
In a published petition, 1-hPG of 8.6 mmol/L be was proposed
as a cut-point for diagnosing impaired glucose tolerance, based
on a number of large population-based studies41. One advan-
tage of 1-h OGTT compared with 2-h OGTT is that it requires
less time, whereas both can identify abnormalities in glucose
excursions after a glucose load. Both measures had similar abili-
ties to predict type 2 diabetes in Native Americans, and the
authors concluded that 1-hPG is an alternative method of iden-
tifying individuals with an elevated risk of type 2 diabetes 42. In
a comparative study of different amounts of glucose loads in
individuals without diabetes, a 50-g and 75-g load produced
similar 1-hPG levels43. Therefore, we decided to use a 50-g glu-
cose load, and 8.6 mmol/L as the cut-point to define dysg-
lycemia in the present study; 1-hPG identified 60% of all
participants with dysglycemia. This is the first time that the
1-hPG value has been used instead of the 2-hPG value to
develop a diabetes risk score.
In keeping with several other studies44–46, we showed that
without using an OGTT, a large proportion of people with dys-
glycemia would remain undetected.
To ensure reliability and standardization of data collection,
medical students, well trained for the survey methodology, per-
formed data collection and carried out measurements by stan-
dardized instruments, recording all medications and
supplements, resulting in a high-quality data collection. Further-
more, collected blood samples were sent regularly to an interna-
tionally accredited central laboratory for analysis to avoid
interlaboratory variability.
The plan was to recruit 300 individuals in each 10-year age
stratum, but finding sufficient numbers of individuals without
diabetes aged ≥35 years was a challenge. We extended the
recruitment period for another 3 months, with only little fur-
ther success. This prompted us to use the age group <35 years
as the reference group for risk assessment, when in the FIN-
DRISC it is 45 years. Indeed, a similar approach was adopted
in two of the previous studies28,30.
An AUC of 1.0 would indicate perfect discrimination; that is,
100% accuracy. An average AUC of 0.77 was found among
Table 3 | Prevalence of dysglycemia according to sex and age in the Saudi glycemia
All Men Women P-value
% n % n % n
Age group
<35 years (n = 926) 14 128 15 87 11 41 0.097
35–44 years (n = 261) 36 93 43 57 28 36 0.020
45–54 years (n = 135) 44 60 49 26 42 34 0.478
55–64 years (n = 60) 53 32 60 15 49 17 0.439
≥65 years (n = 21) 71 15 77 10 63 5 0.631
All (total n = 1,403, men n = 791, women n = 612) 23 328 25 195 22 133 0.204
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approximately 100 studies of models predicting all-cause mor-
tality47. In general, an AUC value of 0.70 indicated a good
model, and 0.80 a very good model48. Thus, the 0.76 AUC of
the SADRISC shows that it can effectively distinguish people at
low dysglycemia risk from those with high risk. As SADRISC
only includes five variables that are easy to define even by lay
people, it offers a useful tool for the first step in screening for
dysglycemia risk in Saudi Arabia.
Table 4 | Comparison of measures of glycemic parameters, demographic, anthropometric and lifestyle characteristics between dysglycemic and
normoglycemic individuals
Normoglycemia (n = 1,075) Dysglycemia (n = 328) P-value
Fasting plasma glucose, mmol/L (mean – SD) 4.1 – 0.9 5.3 – 2.1 <0.001
1-h plasma glucose, mmol/L (mean – SD) 5.8 – 1.6 9.2 – 3.4 <0.001
HbA1c, % (mean – SD) 4.98 – 0.9 5.8 – 1.1 <0.001
Age, years (mean – SD) 30.2 – 9.9 39.8 – 13 <0.001
Sex
Male, n = 791 (n) 596 (55.4%) 195 (59.5%) 0.204
Female, n = 612 (n) 479 (44.6%) 133 (40.5%)
BMI kg/m2 (n)
<25 435 (40.5%) 60 (18.3%) <0.001
25–<30 380 (35.3%) 113 (34.5%)
≥30 260 (24.2%) 155 (47.3%)
Waist circumference, cm (n)*
Normal (men <94 cm, women <80 cm ) 468 (44.4%) 55 (17.1%) <0.001
Abdominal obesity level 1 (men >94–102 cm, women >80–88 cm) 244 (23.1%) 86 (26.7%)
Abdominal obesity level 2 (men >102 cm, women >88 cm) 342 (32.4%) 181 (56.2%)
Ethnic origin (n)
Arabian tribes 830 (77.2%) 240 (73.2%) 0.031
African tribes 52 (4.8%) 20 (6.1%)
Mediterranean countries 48 (4.5%) 19 (5.8%)
Indian continent 62 (5.8%) 33 (10.1%)
Central Asia 19 (1.8%) 1 (0.3%)
South East Asia 30 (2.8%) 8 (2.4%)
Mixed 34 (3.2) 7 (2.1%)
Smoking status (n)
Non-smokers 734 (68.3%) 222 (67.7%) 0.100
Current smokers 227 (21.1%) 76 (23.2%)
Passive smokers 83 (7.7%) 15 (4.6)
Previous smokers 31 (2.9%) 15 (4.6%)
Physical activity, 30 min/day–5 days/week (n)
No 584 (54.3%) 206 (62.8%) 0.004
Yes 491 (45.7%) 122 (37.2%)
Sleep duration, h (n)
<5 77 (7.2%) 39 (11.9%) 0.057
5–6 331 (30.8%) 106 (32.3%)
>6–7 333 (31%) 94 (28.7%)
>7–8 234 (21.8%) 59 (18%)
>8 100 (9.3%) 30 (9.1%)
Sitting hours/day (n)
<4 192 (17.8%) 71 (21.6%) 0.412
4–5 326 (30.3%) 100 (30.5%)
6–8 344 (32.0%) 94 (28.7%)
>8 213 (19.8%) 63 (19.2%)
Daily fruit or vegetable intake (at least one portion) (n)
No 392 (36.5%) 119 (36.3%) 0.951
Yes 683 (63.5%) 209 (63.7%)
The significant values are highlighted in bold. *n, total number of subjects in all subgroups; n, number of subjects in subgroup; n = 1,376.
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For use of a prediction score, such as the SADRISC, it is
necessary to consider a cut-off value to be used for further
action; that is, glycemia testing and preventive management.
People at high risk should be informed, so that they can take
appropriate actions. Laboratory testing for glycemia requires
visits to a healthcare facility. Therefore, the selection of a cut-
off point is a trade-off between the level of risk of the disease
and available resources for the needs of people at high risk. A
lower cut-off score value would increase sensitivity (identify
more people who potentially might develop the disease), but
would also increase the number of false positives (people who
might not develop the disease in the near future or ever) being
referred for follow-up diagnostic testing. It seems that the most
practical cut-point to be used for the SADRISC is 5 or
6 points, which would label 43% and 39% of the population as
high risk, respectively, with the sensitivity and specificity being
approximately 0.70. With 5 points as the cut-point, everyone
aged ≥55 years, and with 6 points, everyone aged ≥65 years
were considered to be at high risk. This makes sense, as more
than half of people aged ≥55 years had dysglycemia. Although
a risk score might not be required for Saudi people aged
≥55 years to determine if they require glycemia testing, a risk
Table 5 | Unadjusted and adjusted odds ratios (95% confidence intervals) for predictors of dysglycemia in the Saudi glycemia screening
participants
Unadjusted Adjusted
OR 95% CI OR 95% CI
Sex
Men Ref Ref
Women 0.85 0.66–1.09 0.51 0.37–0.70
Age group
<35 years Ref Ref
35–44 years 3.45 2.52–4.73 2.92 2.07–4.11
45–54 years 4.99 3.39–7.35 4.04 2.60–6.27
55–64 years 7.13 4.15–12.23 5.22 2.86–9.53
>64 years 15.59 5.94–40.91 8.58 3.02–24.38
Body mass index
<25 kg/m2 Ref Ref
25–30 kg/m2 2.16 1.53–3.04 1.21 0.79–1.84
>30 kg/m2 4.31 3.08–6.03 1.81 1.08–3.05
Waist cirumference FINDRISC
<94 cm (men)/<80 cm (women) Ref Ref
94–102 cm (men)/80–88 cm (women) 2.99 2.07–4.35 2.29 1.48–3.53
>102 cm (men)/>88 cm (women) 4.50 3.23–6.28 1.80 1.07–3.03
30 min daily physical activity
Yes Ref Ref
No 1.42 1.10–1.83 1.27 0.95–1.69
Daily fruit or vegetable intake
No Ref Ref
Yes 1.01 0.78–1.303 0.98 0.73–1.32
Hours of sleep daily
<6 h 1.32 1.02–1.71 1.20 0.89–1.60
6–8 h Ref Ref
>8 h 1.11 0.71–1.74 1.49 0.88–2.51
Use of blood pressure lowering medication
No Ref Ref
Yes 5.02 2.96–8.52 1.62 0.87–3.00
Past history of hyperglycemia (in a medical checkup, during an illness or pregnancy)
No Ref Ref
Yes 2.28 1.52–3.44 1.56 0.96–2.53
Family history of diabetes mellitus
No Ref Ref
Yes: grandparent, uncle, aunt or cousin 0.53 0.31–0.91 1.01 0.56–1.82
Yes: Biological father, mother or sibling 1.75 1.33–2.29 1.80 1.33–2.45
CI, confidence interval; FINDRISC, Finnish Diabetes Risk Score; Ref, reference.
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score is important to identify their level of risk. This should
then determine their priority for interventions giving priority to
those people with the highest risk score.
The comparison of the discrimination ability between the
FINDRISC and SADRISC showed that it is important to vali-
date the risk score in the population where it is going to be
applied. Although the FINDRISC performed relatively well also
in the Saudi population, it was inferior to the SADRISC, which
was based on local data. The reasons for this difference can
only be speculated. They might include the effects of ethnicity/
genetic factors, but also lifestyle factors. It is well-known that
obesity and sedentary lifestyle in Saudi Arabia are more com-
mon than those in Finland. These factors also are likely reasons
for the higher prevalence of dysglycemia at a younger age
Table 6 | Final model for the beta-coefficients and adjusted odds ratios (95% confidence intervals) of the predictors of dysglycemia included in the
Saudi Arabian Diabetes Risk Score with the score weights
Beta coefficient Adjusted Score
OR 95% CI
Sex
Women Ref 0
Men 0.71 2.03 1.50–2.74 2
Age group
<35 years Ref 0
35–44 years 1.06 2.87 2.05–4.03 3
45–54 years 1.40 4.05 2.64–6.21 4
55–64 years 1.77 5.84 3.29–10.38 5
>64 years 2.37 10.74 3.95–29.21 6
Waist circumference FINDRISC
<94 cm (men)/<80 cm (women) Ref 0
94–102 cm (men)/80–88 cm (women) 0.94 2.57 1.74–3.80 3
>102 cm (men)/>88 cm (women) 1.05 2.85 1.97–4.12 3
Past history of hyperglycemia (in a medical checkup, during an illness or pregnancy)
No Ref 0
Yes 0.48 1.62 1.01–2.60 2
Family history of diabetes mellitus
No Ref 0
Yes: grandparent, uncle, aunt or cousin 0.01 1.01 0.56–1.80 0
Yes: Biological father, mother or sibling 0.59 1.81 1.34–2.44 2
Total maximum points 15
CI, confidence interval; FINDRISC, Finnish Diabetes Risk Score; Ref, reference.
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Figure 2 | Receiver operating characteristic (ROC) curves for the prevalence of dysglycemia for the Saudi Arabian Diabetes Risk Score (SADRISC)
and the original Finnish Diabetes Risk Score (FINDRISC) in the Saudi glycemia screening participants.
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compared with Finland. In the present sample, Saudi people
aged 35–44 years had a threefold increased risk of dysglycemia
compared with those aged <35 years.
Even though care was taken to avoid the pitfalls noted in
earlier studies, a few limitations to the present study appeared
during implementation due to reasons beyond our control.
First, the targeted number of older age groups could not be
reached, and just 21 people aged >64 years, and 60 people aged
55–64 years were included. The selection criteria used led to
the exclusion of most of the likely candidates, as they were
already diagnosed with diabetes or one of the other conditions
in the exclusion criteria. We extended the data collection per-
iod, but did not reach our original target sample size. Com-
pared with some other studies, our sample size was not very
large, and only large effects could be detected. Nevertheless, the
performance of SADRISC assessed by AUC was good. Also, we
did not have the opportunity to recruit a validation cohort to
confirm the results from the model development sample. Such
a validation will be carried out in the future in other parts of
Saudi Arabia, and we also plan to apply the SADRISC model
in other population cohorts existing in other Gulf countries.
However, the results obtained are considered quite acceptable
from a public health point of view. Unfortunately, as seen in
other similar studies, detailed assessment of physical activity
and diet was not possible, as they require much more detailed
and elaborated data that cannot be collected in primary care
when screening for dysglycemia risk is carried out. Therefore,
these important risk factors for type 2 diabetes were not
included in the final SADRISC model.
Data from 74 people were excluded due to incompleteness,
with the main reasons being not attending the second visit for
OGTT, hemolysis of blood samples or missing labels on sample
tubes. Thus, exclusion was quite random, and not selectively
occurring, hence it should not jeopardize the validity of the
results.
The present study had many points of strength. First, the
methods used for data collection were well standardized, and
data collectors were all well trained. Second, the selection of
PHCCs and participants were randomized to avoid bias, and
the collected sample reflected the multiethnic nature of the city
population, which was very similar to earlier published data26.
Furthermore, a combination of HbA1c and OGTT was used to
detect dysglycemia, which is the most comprehensive way of
defining the condition, ensuring the detection of all possible
cases. Furthermore, the accuracy of the laboratory results was
assured by carrying out all measurements in one accredited lab-
oratory.
In conclusion, we have managed to complete our intended
task of developing a valid and easy to administer tool, which is
the first step in screening for dysglycemia risk. The AUC of
0.76 of the SADRISC shows that it can effectively distinguish
people at high dysglycemia risk. Efforts will be made to intro-
duce it to health professionals and the public in Saudi Arabia
through various methods, by coordinating with the Ministry of
Health. Thus, we hope that the SADRISC will contribute to the
implemention of a national type 2 diabetes prevention strategy
aiming at reversing the increasing trend in the prevalence of
type 2 diabetes in Saudi Arabia.
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